<p>Woodline Partners LP 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免费报告）股票中的持仓增加了 111.8%。该公司在此期间额外购买了 680,148 股后，持有该专业制药公司 1,288,401 股股票。到最近一个季度末，Woodline Partners LP 持有的 KalVista Pharmaceuticals 股票约占 2.61%，价值 10,913,000 美元。</p>
<p>其他机构投资者和对冲基金最近也增加或减少了在该公司的股份。SG Americas Securities LLC 在第四季度将其在 KalVista Pharmaceuticals 的持仓提高了 10.0%。SG Americas Securities LLC 目前持有 14,508 股该专业制药公司的股票，价值 123,000 美元，此前在此期间额外购买了 1,319 股。Tower Research Capital LLC TRC 在第四季度将其在 KalVista Pharmaceuticals 的股份提高了 666.9%。Tower Research Capital LLC TRC 目前持有 6,327 股该专业制药公司的股票，价值 54,000 美元，此前在上个季度购买了 5,502 股。Dimensional Fund Advisors LP 在第四季度将其在 KalVista Pharmaceuticals 的持仓提高了 14.7%。Dimensional Fund Advisors LP 目前持有 696,037 股该专业制药公司的股票，价值 5,895,000 美元，此前在此期间额外购买了 89,001 股。Wellington Management Group LLP 在第四季度将其在 KalVista Pharmaceuticals 的股份提高了 4.2%。Wellington Management Group LLP 目前持有 122,863 股该专业制药公司的股票，价值 1,041,000 美元，此前在上个季度购买了 4,940 股。最后，Wells Fargo &amp; Company MN 在第四季度将其在 KalVista Pharmaceuticals 的股份提高了 29.1%。Wells Fargo &amp; Company MN 目前持有 20,165 股该专业制药公司的股票，价值 171,000 美元，此前在上个季度购买了 4,543 股。</p>
<h2>KalVista Pharmaceuticals 的内部买卖</h2>
<p>在其他消息中，内部人士 Paul K. Audhya 于 5 月 19 日星期一出售了 2,776 股该股票。股票以平均价格 11.84 美元出售，总交易额为 32,867.84 美元。出售后，内部人士现在持有该公司 106,611 股股票，价值约 1,262,274.24 美元。这代表其持股比例减少了 2.54%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，首席执行官 Benjamin L. Palleiko 于 5 月 19 日星期一出售了 3,808 股 KalVista Pharmaceuticals 股票。股票以平均价格 11.84 美元出售，总价值为 45,086.72 美元。交易完成后，首席执行官现在直接持有 293,367 股该公司的股票，价值 3,473,465.28 美元。这代表其持股比例减少了 1.28%。该出售的披露信息可以在这里找到。内部人士在过去九十天内共出售了价值 181,770 美元的 15,647 股公司股票。公司内部人士持有该公司 10.50% 的股票。</p>
<h2>KalVista Pharmaceuticals 股票表现</h2>
<p>KALV 在星期五开盘价为 11.42 美元。KalVista Pharmaceuticals, Inc. 的 12 个月低点为 7.30 美元，12 个月高点为 15.50 美元。该公司的市值为 5.6776 亿美元，市盈率为 -3.14，贝塔值为 0.05。该公司的 50 日简单移动平均线为 11.97 美元，200 日简单移动平均线为 10.45 美元。</p>
<h2>分析师评级变动</h2>
<p>一些股票分析师最近对 KALV 股票发布了报告。JMP Securities 在 1 月 31 日星期五的研究报告中启动了对 KalVista Pharmaceuticals 股票的覆盖。他们给予该公司 &#34;跑赢大盘&#34; 的评级，目标价为 19.00 美元。Jones Trading 在 3 月 26 日星期三的研究报告中重申了 &#34;买入&#34; 评级，并给予 KalVista Pharmaceuticals 股票 30.00 美元的目标价。Needham &amp; Company LLC 在 4 月 8 日星期二的研究报告中重申了 &#34;买入&#34; 评级，并设定了 28.00 美元的目标价。HC Wainwright 在 3 月 14 日星期五的报告中重申了 &#34;买入&#34; 评级，并设定了 20.00 美元的目标价。最后，Citizens Jmp 在 1 月 31 日星期五的研究报告中将 KalVista Pharmaceuticals 的评级上调至 &#34;强力买入&#34;。七位股票研究分析师对该股票给予了买入评级，一位分析师给予了该公司股票强力买入评级。根据 MarketBeat.com，该公司目前的平均评级为 &#34;买入&#34;，平均目标价为 24.83 美元。</p>
<p><strong>查看我们对 KALV 的最新分析</strong></p>
<h2>关于 KalVista Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>KalVista Pharmaceuticals, Inc. 是一家临床阶段的制药公司，专注于发现、开发和商业化针对未满足需求疾病的药物疗法抑制剂。该公司的产品候选药物是 Sebetralstat，一种小分子血浆激肽酶抑制剂，针对遗传性血管性水肿（HAE）疾病。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 KalVista Pharmaceuticals 更好</li>
<li>股票评级和建议：理解分析师评级</li>
<li>Joby 股票的动荡：近期下跌的原因是什么？</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>超级微型计算机股票在沙特订单中开辟新路径</li>
</ul>
<p><strong>想看看其他对冲基金持有 KALV 的情况吗？</strong> 访问 HoldingsChannel.com 获取 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 KalVista 制药吗？</h2>
<p>在考虑 KalVista 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 KalVista 制药并不在名单上。</p>
<p>虽然 KalVista 制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KalVista制药

<p>Woodline Partners LP 在第四季度将其在 KalVista Pharmaceuticals 的持股增加了 111.8%，收购了 680,148 股，使其总持股达到 1,288,401 股，价值 1,090 万美元。其他机构投资者也调整了他们的持仓。内部人士进行了股票出售，首席执行官 Benjamin L. Palleiko 和内部人士 Paul K. Audhya 出售了股份。KalVista 的股票开盘价为 11.42 美元，市值为 5.6776 亿美元。分析师们给予了积极的评级，平均目标价为 24.83 美元</p>

<p>Woodline Partners LP boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 111.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 1,288,401 shares of the specialty pharmaceutical company's stock after acquiring an additional 680,148 shares during the period. Woodline Partners LP owned approximately 2.61% of KalVista Pharmaceuticals worth $10,913,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Woodline Partners LP 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免费报告）股票中的持仓增加了 111.8%。该公司在此期间额外购买了 680,148 股后，持有该专业制药公司 1,288,401 股股票。到最近一个季度末，Woodline Partners LP 持有的 KalVista Pharmaceuticals 股票约占 2.61%，价值 10,913,000 美元。</p>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after acquiring an additional 1,319 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 5,502 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in KalVista Pharmaceuticals by 14.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock worth $5,895,000 after purchasing an additional 89,001 shares during the period. Wellington Management Group LLP boosted its stake in KalVista Pharmaceuticals by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock worth $1,041,000 after buying an additional 4,940 shares in the last quarter. Finally, Wells Fargo &amp; Company MN boosted its stake in KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo &amp; Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock worth $171,000 after buying an additional 4,543 shares in the last quarter.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也增加或减少了在该公司的股份。SG Americas Securities LLC 在第四季度将其在 KalVista Pharmaceuticals 的持仓提高了 10.0%。SG Americas Securities LLC 目前持有 14,508 股该专业制药公司的股票，价值 123,000 美元，此前在此期间额外购买了 1,319 股。Tower Research Capital LLC TRC 在第四季度将其在 KalVista Pharmaceuticals 的股份提高了 666.9%。Tower Research Capital LLC TRC 目前持有 6,327 股该专业制药公司的股票，价值 54,000 美元，此前在上个季度购买了 5,502 股。Dimensional Fund Advisors LP 在第四季度将其在 KalVista Pharmaceuticals 的持仓提高了 14.7%。Dimensional Fund Advisors LP 目前持有 696,037 股该专业制药公司的股票，价值 5,895,000 美元，此前在此期间额外购买了 89,001 股。Wellington Management Group LLP 在第四季度将其在 KalVista Pharmaceuticals 的股份提高了 4.2%。Wellington Management Group LLP 目前持有 122,863 股该专业制药公司的股票，价值 1,041,000 美元，此前在上个季度购买了 4,940 股。最后，Wells Fargo &amp; Company MN 在第四季度将其在 KalVista Pharmaceuticals 的股份提高了 29.1%。Wells Fargo &amp; Company MN 目前持有 20,165 股该专业制药公司的股票，价值 171,000 美元，此前在上个季度购买了 4,543 股。</p>
</div><h2>Insider Buying and Selling at KalVista Pharmaceuticals</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 的内部买卖</h2>
</div><p>In other news, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider now owns 106,611 shares in the company, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 3,808 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $45,086.72. Following the completion of the transaction, the chief executive officer now directly owns 293,367 shares of the company's stock, valued at $3,473,465.28. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,647 shares of company stock worth $181,770 over the last ninety days. Corporate insiders own 10.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Paul K. Audhya 于 5 月 19 日星期一出售了 2,776 股该股票。股票以平均价格 11.84 美元出售，总交易额为 32,867.84 美元。出售后，内部人士现在持有该公司 106,611 股股票，价值约 1,262,274.24 美元。这代表其持股比例减少了 2.54%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，首席执行官 Benjamin L. Palleiko 于 5 月 19 日星期一出售了 3,808 股 KalVista Pharmaceuticals 股票。股票以平均价格 11.84 美元出售，总价值为 45,086.72 美元。交易完成后，首席执行官现在直接持有 293,367 股该公司的股票，价值 3,473,465.28 美元。这代表其持股比例减少了 1.28%。该出售的披露信息可以在这里找到。内部人士在过去九十天内共出售了价值 181,770 美元的 15,647 股公司股票。公司内部人士持有该公司 10.50% 的股票。</p>
</div><h2>KalVista Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 股票表现</h2>
</div><p>KALV opened at $11.42 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The firm has a market cap of $567.76 million, a price-to-earnings ratio of -3.14 and a beta of 0.05. The firm's 50-day simple moving average is $11.97 and its 200-day simple moving average is $10.45.</p>
<div class="lb-trans"><p>KALV 在星期五开盘价为 11.42 美元。KalVista Pharmaceuticals, Inc. 的 12 个月低点为 7.30 美元，12 个月高点为 15.50 美元。该公司的市值为 5.6776 亿美元，市盈率为 -3.14，贝塔值为 0.05。该公司的 50 日简单移动平均线为 11.97 美元，200 日简单移动平均线为 10.45 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities analysts have recently issued reports on KALV shares. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an &#34;outperform&#34; rating and a $19.00 price objective for the company. Jones Trading reissued a &#34;buy&#34; rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Citizens Jmp upgraded KalVista Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Friday, January 31st. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and an average price target of $24.83.</p>
<div class="lb-trans"><p>一些股票分析师最近对 KALV 股票发布了报告。JMP Securities 在 1 月 31 日星期五的研究报告中启动了对 KalVista Pharmaceuticals 股票的覆盖。他们给予该公司 &#34;跑赢大盘&#34; 的评级，目标价为 19.00 美元。Jones Trading 在 3 月 26 日星期三的研究报告中重申了 &#34;买入&#34; 评级，并给予 KalVista Pharmaceuticals 股票 30.00 美元的目标价。Needham &amp; Company LLC 在 4 月 8 日星期二的研究报告中重申了 &#34;买入&#34; 评级，并设定了 28.00 美元的目标价。HC Wainwright 在 3 月 14 日星期五的报告中重申了 &#34;买入&#34; 评级，并设定了 20.00 美元的目标价。最后，Citizens Jmp 在 1 月 31 日星期五的研究报告中将 KalVista Pharmaceuticals 的评级上调至 &#34;强力买入&#34;。七位股票研究分析师对该股票给予了买入评级，一位分析师给予了该公司股票强力买入评级。根据 MarketBeat.com，该公司目前的平均评级为 &#34;买入&#34;，平均目标价为 24.83 美元。</p>
</div><p><strong>View Our Latest Analysis on KALV</strong></p>
<div class="lb-trans"><p><strong>查看我们对 KALV 的最新分析</strong></p>
</div><h2>About KalVista Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 KalVista Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals, Inc. 是一家临床阶段的制药公司，专注于发现、开发和商业化针对未满足需求疾病的药物疗法抑制剂。该公司的产品候选药物是 Sebetralstat，一种小分子血浆激肽酶抑制剂，针对遗传性血管性水肿（HAE）疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than KalVista Pharmaceuticals</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 KalVista Pharmaceuticals 更好</li>
<li>股票评级和建议：理解分析师评级</li>
<li>Joby 股票的动荡：近期下跌的原因是什么？</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>超级微型计算机股票在沙特订单中开辟新路径</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding KALV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 KALV 的情况吗？</strong> 访问 HoldingsChannel.com 获取 KalVista Pharmaceuticals, Inc.（NASDAQ:KALV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KALV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in KalVista Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 KalVista 制药吗？</h2>
</div><p>Before you consider KalVista Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 KalVista 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 KalVista 制药并不在名单上。</p>
</div><p>While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 KalVista 制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Woodline Partners LP 购入了 680,148 股 KalVista 制药公司（NASDAQ:KALV）的股票